Workload guidelines met with resistance from Missouri Faculty Council
columbiatribune.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from columbiatribune.com Daily Mail and Mail on Sunday newspapers.
Workload guidelines met with resistance from Missouri Faculty Council
therolladailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from therolladailynews.com Daily Mail and Mail on Sunday newspapers.
About PolyPeptide Group
PolyPeptide is a Contract Development & Manufacturing Organization (CDMO) focusing on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development as well as in generic products. Dating back to 1952, PolyPeptide today manufactures around one-half of all currently approved peptide drug substances with a global footprint of six GMP-certified facilities in Europe, the U.S. and India. As a multinational company with more than 900 employees, its diversity brings breadth, depth of knowledge and experience to the group. PolyPeptide has grown organically and by selective acquisition of existing expertise, culminating in its position today as a leader in outsourced peptide manufacturing. PolyPeptide s shares (SIX: PPGN) are listed on the Swiss Stock Exchange. For more information, visit polypeptide.com.
International PolyPeptide Group Chooses SIX For Its IPO Date
29/04/2021
Today, PolyPeptide Group AG (Ticker PPGN ), a global leader in peptide development and manufacturing, listed its shares on the Swiss Stock Exchange. The opening price was CHF 72.50 per share, resulting in a market capitalization of CHF 2.4 billion.
With PolyPeptide Group, SIX welcomes another company from the life sciences sector, further expanding its strong peer group and strengthening its position as Europe’s leading exchange for life sciences companies.
The issued share capital of PolyPeptide comprises of 33,125,001 registered shares, whereas 3,125,000 newly issued registered shares together with existing 8,396,740 registered shares were offered in the IPO. At an issue price of CHF 64.00 per registered share, the placement volume was CHF 737 million (excluding over-allotment option). In addition, the selling shareholder has granted an overallotment option of up to 1,728,261 existing shares.